Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum.
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
18
06
2020
revised:
02
09
2020
accepted:
03
11
2020
pubmed:
11
11
2020
medline:
15
12
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
Gleason score, a measure of prostate tumor differentiation, is the strongest predictor of lethal prostate cancer at the time of diagnosis. Metabolomic profiling of tumor and of patient serum could identify biomarkers of aggressive disease and lead to the development of a less-invasive assay to perform active surveillance monitoring. Metabolomic profiling of prostate tissue and serum samples was performed. Metabolite levels and metabolite sets were compared across Gleason scores. Machine learning algorithms were trained and tuned to predict transformation or differentiation status from metabolite data. A total of 135 metabolites were significantly different (
Identifiants
pubmed: 33168599
pii: 1541-7786.MCR-20-0548
doi: 10.1158/1541-7786.MCR-20-0548
pmc: PMC8369519
mid: NIHMS1729885
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
475-484Subventions
Organisme : NCI NIH HHS
ID : P50 CA090381
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211024
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA131945
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2020 American Association for Cancer Research.
Références
Cancer Sci. 2020 Apr;111(4):1218-1227
pubmed: 31997472
Cancer Res. 1984 Oct;44(10):4224-32
pubmed: 6380705
Biochem Soc Trans. 1987 Aug;15(4):728-30
pubmed: 3678588
Am J Surg Pathol. 2003 Oct;27(10):1291-301
pubmed: 14508390
Sci Rep. 2016 Dec 02;6:38243
pubmed: 27910903
J Clin Oncol. 2009 Jul 20;27(21):3459-64
pubmed: 19433685
Clin Genitourin Cancer. 2006 Jun;5(1):61-6
pubmed: 16859581
Crit Rev Clin Lab Sci. 2006;43(2):143-81
pubmed: 16517421
Curr Opin Urol. 2015 Jan;25(1):65-70
pubmed: 25405934
PLoS One. 2013 Apr 23;8(4):e62375
pubmed: 23626811
Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):887-906
pubmed: 27197278
Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):
pubmed: 29229664
Curr Opin Oncol. 2016 May;28(3):248-52
pubmed: 26974844
Artif Intell Med. 2020 Apr;104:101822
pubmed: 32499001
J Clin Oncol. 2011 Jun 10;29(17):2391-6
pubmed: 21537050
Prostate. 2013 Oct;73(14):1547-60
pubmed: 23824564
Prostate Cancer Prostatic Dis. 2006;9(3):230-4
pubmed: 16683009
Clin Cancer Res. 2017 Jan 1;23(1):81-87
pubmed: 27663590
Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52
pubmed: 15386533
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):244-51
pubmed: 25841621
J Proteome Res. 2011 Mar 4;10(3):1361-73
pubmed: 21166384
Cell Metab. 2013 Aug 6;18(2):153-61
pubmed: 23791484
Clin Genitourin Cancer. 2018 Jun;16(3):226-234
pubmed: 29196209
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Mol Cancer Res. 2019 May;17(5):1155-1165
pubmed: 30745465
Curr Urol. 2017 Aug;10(3):118-125
pubmed: 28878593
Br J Cancer. 2020 Jul;123(1):137-147
pubmed: 32390008
Cancer Res. 2014 Dec 15;74(24):7198-204
pubmed: 25322691
Mol Cancer Res. 2017 Apr;15(4):439-447
pubmed: 28074002
Urol Oncol. 2015 Jul;33(7):329.e13-9
pubmed: 25960411
J Cell Biol. 2018 Jul 2;217(7):2291-2298
pubmed: 29915025
J Proteome Res. 2013 Sep 6;12(9):3865-73
pubmed: 23885889
Metabolomics. 2018 Sep 20;14(10):128
pubmed: 30830398
Bioinformatics. 2008 Dec 15;24(24):2908-14
pubmed: 18815183
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
JAMA. 2019 Feb 19;321(7):704-706
pubmed: 30743264
Oxid Med Cell Longev. 2013;2013:972913
pubmed: 23766865
Curr Opin Pharmacol. 2010 Aug;10(4):362-8
pubmed: 20627682